Literature DB >> 35426156

In vitro human cell-based aneugen molecular mechanism assay.

Nikki E Hall1, Kyle Tichenor1, Steven M Bryce1, Jeffrey C Bemis1, Stephen D Dertinger1.   

Abstract

This laboratory previously described an in vitro human cell-based assay and data analysis scheme that discriminates common molecular targets responsible for chemical-induced in vitro aneugenicity: tubulin destabilization, tubulin stabilization, and inhibition of Aurora kinases (Bernacki et al., Toxicol. Sci. 170 [2019] 382-393). The current report describes updated procedures that simplify benchtop processing and data analysis methods. For these experiments, human lymphoblastoid TK6 cells were exposed to each of 25 aneugens over a range of concentrations in the presence of fluorescent paclitaxel (488 Taxol). After a 4 h treatment period, cells were lysed and nuclei were stained with a nucleic acid dye and labeled with fluorescent antibodies against phospho-histone H3 (p-H3). Flow cytometric analyses revealed several unique signatures: tubulin stabilizers caused increased frequencies of p-H3-positive events with concentration-dependent increases in 488 Taxol-associated fluorescence; tubulin destabilizers caused increased frequencies of p-H3-positive events with concomitant decreases in 488 Taxol-associated fluorescence; and Aurora kinase B inhibitors caused reduced frequencies of p-H3-positive events and lower median fluorescent intensities of p-H3-positive events. These results demonstrate a simple rubric based on 488 Taxol- and p-H3-associated metrics can reliably discriminate between several commonly encountered aneugenic molecular mechanisms.
© 2022 Environmental Mutagen Society.

Entities:  

Keywords:  TK6 cells; aneugen; aurora kinase inhibitors; flow cytometry; microtubules

Mesh:

Substances:

Year:  2022        PMID: 35426156      PMCID: PMC9106857          DOI: 10.1002/em.22480

Source DB:  PubMed          Journal:  Environ Mol Mutagen        ISSN: 0893-6692            Impact factor:   3.579


  41 in total

1.  PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.

Authors:  Jitesh P Jani; Joel Arcari; Vincent Bernardo; Samit K Bhattacharya; David Briere; Bruce D Cohen; Kevin Coleman; James G Christensen; Erling O Emerson; Amy Jakowski; Kenneth Hook; Gerrit Los; James D Moyer; Ingrid Pruimboom-Brees; Leslie Pustilnik; Ann Marie Rossi; Stefan J Steyn; Chunyan Su; Konstantinos Tsaparikos; Donn Wishka; Kwansik Yoon; John L Jakubczak
Journal:  Mol Cancer Ther       Date:  2010-03-30       Impact factor: 6.261

2.  Investigating the Generalizability of the MultiFlow ® DNA Damage Assay and Several Companion Machine Learning Models With a Set of 103 Diverse Test Chemicals.

Authors:  Steven M Bryce; Derek T Bernacki; Stephanie L Smith-Roe; Kristine L Witt; Jeffrey C Bemis; Stephen D Dertinger
Journal:  Toxicol Sci       Date:  2018-03-01       Impact factor: 4.849

3.  A Contaminant Impurity, Not Rigosertib, Is a Tubulin Binding Agent.

Authors:  Stacey J Baker; Stephen C Cosenza; Saikrishna Athuluri-Divakar; M V Ramana Reddy; Rodrigo Vasquez-Del Carpio; Rinku Jain; Aneel K Aggarwal; E Premkumar Reddy
Journal:  Mol Cell       Date:  2020-07-02       Impact factor: 17.970

4.  Noscapine hydrochloride disrupts the mitotic spindle in mammalian cells and induces aneuploidy as well as polyploidy in cultured human lymphocytes.

Authors:  M Schuler; P Muehlbauer; P Guzzie; D A Eastmond
Journal:  Mutagenesis       Date:  1999-01       Impact factor: 3.000

5.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

6.  Clastogenic and aneugenic effects of three benzimidazole derivatives in the in vitro micronucleus test using human lymphocytes.

Authors:  P Van Hummelen; A Elhajouji; M Kirsch-Volders
Journal:  Mutagenesis       Date:  1995-01       Impact factor: 3.000

7.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity.

Authors:  Theonie Anastassiadis; Sean W Deacon; Karthik Devarajan; Haiching Ma; Jeffrey R Peterson
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

8.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Authors:  Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

9.  A mode-of-action approach for the identification of genotoxic carcinogens.

Authors:  Lya G Hernández; Jan van Benthem; George E Johnson
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

10.  Genotoxicity of flubendazole and its metabolites in vitro and the impact of a new formulation on in vivo aneugenicity.

Authors:  David J Tweats; George E Johnson; Ivan Scandale; James Whitwell; Dean B Evans
Journal:  Mutagenesis       Date:  2015-10-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.